Effect of Bosentan on Exercise Capacity and Quality of Life in Adults With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease With and Without Down's Syndrome

American Journal of Cardiology

Volumn 103, Issue 9, 2009, Pages 1309-1315

  Duffels, Mariëlle G J ^a   Vis, Jeroen C ^a   van Loon, Rosa L E ^b   Nieuwkerk, Pythia T ^a   van Dijk, Arie P J ^c   Hoendermis, Elke S ^b   de Bruin Bon, Rianne H A C M ^a   Bouma, Berto J ^a   Bresser, Paul ^a   Berger, Rolf M F ^b   Mulder, Barbara J M ^a,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BOSENTAN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIAC PATIENT; CLINICAL EVALUATION; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DOWN SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT; SORE THROAT; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; DOWN SYNDROME; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROBABILITY; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65249164987     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.021     Document Type: Article

References (23)

1. Galie N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M.F., Lauer A., Chiossi E., and Landzberg M. Bosentan Randomized Trial of Endothelin Antagonist Therapy. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
2. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., Rainisio M., Simonneau G., and Rubin L.J. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
3. Provencher S., Sitbon O., Humbert M., Cabrol S., Jais X., and Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595
4. Sitbon O., Badesch D.B., Channick R.N., Frost A., Robbins I.M., Simonneau G., Tapson V.F., and Rubin L.J. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124 (2003) 247-254
5. Keogh A.M., McNeil K.D., Wlodarczyk J., Gabbay E., and Williams T.J. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 26 (2007) 181-187
6. Peacock A., Naeije R., Galie N., and Reeves J.T. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 23 (2004) 947-953
7. Diller G.P., Dimopoulos K., Kaya M.G., Harries C., Uebing A., Li W., Koltsida E., Gibbs J.S., and Gatzoulis M.A. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 93 (2007) 974-976
8. Sitbon O., Beghetti M., Petit J., Iserin L., Humbert M., Gressin V., and Simonneau G. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 36 suppl 3 (2006) 25-31
9. D'Alto M., Vizza C.D., Romeo E., Badagliacca R., Santoro G., Poscia R., Sarubbi B., Mancone M., Argiento P., Ferrante F., et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 93 (2007) 621-625
10. Schulze-Neick I., Gilbert N., Ewert R., Witt C., Gruenig E., Enke B., Borst M.M., Lange P.E., and Hoeper M.M. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 150 (2005) 716.e7-716.e12
11. Duffels M., van Loon L., Berger R., Boonstra A., Vonk-Noordergraaf A., and Mulder B. Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition. Congenital Heart Dis 2 (2007) 242-249
12. Apostolopoulou S.C., Manginas A., Cokkinos D.V., and Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 93 (2007) 350-354
13. van Loon R.L., Hoendermis E.S., Duffels M.G., Vonk-Noordegraaf A., Mulder B.J., Hillege H.L., and Berger R.M. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J 154 (2007) 776-782
14. Duffels M.G., Vis J.C., van Loon R.L., Berger R.M., Hoendermis E.S., van Dijk A.P., Bouma B.J., and Mulder B.J. Down patients with Eisenmenger syndrome: is bosentan treatment an option?. Int J Cardiol (2008) Epub ahead of print
15. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167 (2003) 211-277
16. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
17. Galie N., Hinderliter A.L., Torbicki A., Fourme T., Simonneau G., Pulido T., Espinola-Zavaleta N., Rocchi G., Manes A., Frantz R., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
18. Meluzin J., Spinarova L., Bakala J., Toman J., Krejci J., Hude P., Kara T., and Soucek M. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 22 (2001) 340-348
19. Huez S., Vachiery J.L., Unger P., Brimioulle S., and Naeije R. Tissue Doppler imaging evaluation of cardiac adaptation to severe pulmonary hypertension. Am J Cardiol 100 (2007) 1473-1478
20. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
21. McKenna S.P., Doughty N., Meads D.M., Doward L.C., and Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 15 (2006) 103-115
22. Zlupko M., Harhay M.O., Gallop R., Shin J., Archer-Chicko C., Patel R., Palevsky H.I., and Taichman D.B. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 102 (2008) 1431-1438
23. Suzuki K., Yamaki S., Mimori S., Murakami Y., Mori K., Takahashi Y., and Kikuchi T. Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 86 (2000) 434-437